Buyout firm Advent International is considering the sale of generic drugmaker Zentiva, in a deal that could value the former Sanofi unit at about €5 billion ($5.4 billion), according to people familiar with the matter. Prague-based Zentiva, which traces its roots back to the Black Eagle pharmacy in the 15th century, operates in more than 30 countries, notably the Czech Republic, Slovakia and Romania, according to its website. The drugmaker was nationalized in 1946. The firm’s management acquired a majority share in 1998 and established a new focus on branded generic medicine. In 2018, Advent bought the business from Sanofi for €1.9 billion.
Read the full article: Advent Mulls €5B Sale of Generic Drugmaker Zentiva //
Source: https://finance.yahoo.com/news/advent-mulls-5-billion-sale-104206260.html